Cardiff Oncology
Biotechnology ResearchView the employees at
Cardiff Oncology-
Chuck Monahan Sr. Vice President Regulatory Affairs
-
Rising Star
Ebba Fröjd Registered Nurse på Trovagene-
Segersta, Gavleborg County, Sweden
-
Rising Star
Kristen Lipinski Powers Oncology Diagnostics Manager at Astra Zeneca-
Rising Star
Janelle Vogt Program Management Professional-
Rising Star
Fairooz Kabbinavar M.D., FACP Chief Medical Officer at Cardiff Oncology, San Diego, CA.-
San Diego, California, United States
-
Top 5%
Overview
Cardiff Oncology is a clinical-stage biotechnology company, headquartered in San Diego, CA, leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers. Our lead asset is onvansertib, a PLK1 inhibitor being evaluated in combination with standard-of-care (SoC) therapeutics in clinical programs targeting indications such as KRAS/NRAS-mutated metastatic colorectal cancer (mCRC) and metastatic pancreatic ductal adenocarcinoma (mPDAC), as well as in investigator-initiated trials in triple negative breast cancer (TNBC) and small cell lung cancer (SCLC). These programs and Cardiff's broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SoC alone. For more information, please visit https://www.cardiffoncology.com.
-